Mineralys Therapeutics, Inc.: management transactions · United States · SEC (Form 4)

About Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc. (ticker: MLYS) is a U.S.-based biopharmaceutical company listed on the Nasdaq in the United States. The company is focused on cardiometabolic and cardiorenal disease, with a development strategy centered on hypertension and related comorbidities such as chronic kidney disease (CKD) and obstructive sleep apnea (OSA). From an equity-research perspective, Mineralys fits the profile of a clinical-stage biotech: it has no commercial product revenue yet, and its valuation is primarily driven by clinical execution, regulatory milestones, financing capacity, and the probability of future commercialization. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001933414/000193341426000056/mlys-20251231.htm?utm_source=openai)) Mineralys was incorporated in Delaware in May 2019 and is headquartered in Radnor, Pennsylvania. Its corporate history includes an earlier name, Catalys SC1, Inc., before the company was renamed Mineralys Therapeutics, Inc. The business has followed the classic biotech path of building a pipeline, advancing clinical assets, and funding operations through public markets and other capital raises. The company completed its IPO in February 2023, which helped finance research, clinical trials, and broader development activities. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1933414/000193341424000057/R9.htm?utm_source=openai)) The company’s lead asset is lorundrostat, an orally administered, highly selective aldosterone synthase inhibitor. Mineralys is developing lorundrostat for diseases associated with dysregulated aldosterone, primarily hypertension, but also CKD and OSA. Recent SEC filings indicate that Mineralys has completed two pivotal trials in hypertension and Phase 2 studies in CKD and OSA, which places the program in the advanced clinical-development category. That is an important distinction for investors: the asset is no longer purely preclinical, but it still carries meaningful development and approval risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001933414/000193341426000056/mlys-20251231.htm?utm_source=openai)) In competitive terms, Mineralys is attempting to differentiate itself in a large and crowded hypertension market by targeting aldosterone biology more directly. The rationale is that a more selective mechanism could improve blood-pressure control and potentially address overlapping renal and sleep-apnea comorbidities. For investors, that creates a potentially attractive precision-mechanism thesis, but it also means the stock remains highly sensitive to clinical data readouts, regulatory decisions, and capital-market conditions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001933414/000193341426000056/mlys-20251231.htm?utm_source=openai)) Among the most important recent developments, Mineralys disclosed that it submitted an NDA to the FDA in December 2025 for lorundrostat in hypertension, with a PDUFA target action date of December 22, 2026. The company also completed an upsized public offering in September 2025, raising approximately $287.5 million in gross proceeds to support clinical development, manufacturing, pre-commercial activities, and general corporate purposes. Taken together, these events suggest the company is moving from late-stage clinical execution toward potential commercialization, while still operating with the financing and regulatory profile typical of a development-stage biotech. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001933414/000193341426000056/mlys-20251231.htm?utm_source=openai))